News
UCBJY
138.09
+0.35%
0.48
Weekly Report: what happened at UCBJY last week (1208-1212)?
Weekly Report · 3d ago
UCB SA (0NZT) Gets a Buy from UBS
TipRanks · 3d ago
AstraZeneca: A Rare Compound Growth Opportunity In Biopharma
Seeking Alpha · 12/10 15:26
UCB price target raised to EUR 295 from EUR 285 at Deutsche Bank
TipRanks · 12/08 17:45
UCB price target raised to EUR 300 from EUR 230 at JPMorgan
TipRanks · 12/08 17:25
Weekly Report: what happened at UCBJY last week (1201-1205)?
Weekly Report · 12/08 10:45
UBS Remains a Buy on UCB SA (0NZT)
TipRanks · 12/08 09:56
UCB SA (0NZT) Receives a Buy from Barclays
TipRanks · 12/08 07:36
UCB Upgrades 2025 Guidance
NASDAQ · 12/05 06:29
Berenberg Bank Reaffirms Their Buy Rating on UCB SA (0NZT)
TipRanks · 12/04 06:45
Morgan Stanley Sticks to Its Buy Rating for UCB SA (0NZT)
TipRanks · 12/03 16:38
Weekly Report: what happened at UCBJY last week (1124-1128)?
Weekly Report · 12/01 10:39
UCB SA (0NZT) Gets a Buy from UBS
TipRanks · 12/01 09:45
Barclays Sticks to Their Buy Rating for UCB SA (0NZT)
TipRanks · 12/01 06:55
J&J Halts Alzheimer's Trial After Drug Fails To Slow Clinical Decline
Benzinga · 11/25 17:22
UBS Keeps Their Buy Rating on UCB SA (0NZT)
TipRanks · 11/25 03:15
Weekly Report: what happened at UCBJY last week (1117-1121)?
Weekly Report · 11/24 10:45
Barclays Keeps Their Buy Rating on UCB SA (0NZT)
TipRanks · 11/24 07:56
Weekly Report: what happened at UCBJY last week (1110-1114)?
Weekly Report · 11/17 10:46
Barclays Reaffirms Their Buy Rating on UCB SA (0NZT)
TipRanks · 11/17 06:55
More
Webull provides a variety of real-time UCBJY stock news. You can receive the latest news about Ucb S A through multiple platforms. This information may help you make smarter investment decisions.
About UCBJY
Ucb SA is a Belgium-based biopharmaceutical and specialty chemical company that specializes in two therapeutic areas: diseases of the central nervous system (CNS) and immunology. In the area of central nervous system disorders, the Company is focused on epilepsy, diabetic neuropathic pain, multiple sclerosis, fibromyalgia, restless legs syndrome and Parkinson’s disease, and the area of immunology includes, bone loss disorders, Crohn’s disease, rheumatoid arthritis and respiratory disease. In addition to its core fields of business, Ucb SA delivers molecule solutions to specialists for use in the treatment of severe diseases. Its product portfolio includes drugs, such as Neupro, Vimpat, Cimzia, among others. Ucb SA also operates in primary care to support specialist products that are administered by primary care physicians.